Fatty acid-binding protein 4 as a biomarker for colon adenocarcinoma risk and prognosis: Challenges and future directions

doi:10.4251/wjgo.v17.i8.106621

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=0

Aug 15, 2025 (publication date) through Aug 14, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Aug 15, 2025; 17(8): 106621
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.106621

Fatty acid-binding protein 4 as a biomarker for colon adenocarcinoma risk and prognosis: Challenges and future directions

Si-Rui Wang, Ting-Lan Cao, Hui-Zhong Jiang

Si-Rui Wang, Ting-Lan Cao, Hui-Zhong Jiang, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China

Author contributions: Wang SR wrote the original draft; Jiang HZ contributed to conceptualization, writing, reviewing and editing; Wang SR, Jiang HZ and Cao TL participated in drafting the manuscript; and all authors have read and approved the final version of the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Hui-Zhong Jiang, PhD, Professor, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Beijing 100007, China. jianghz93@126.com

Received: March 3, 2025
Revised: March 27, 2025
Accepted: April 3, 2025
Published online: August 15, 2025
Processing time: 164 Days and 10.5 Hours

Core Tip

Core Tip: Fatty acid-binding protein 4 (FABP4) is a promising biomarker and potential therapeutic target for colon adenocarcinoma diagnosis and prognosis. Our letter calls for a stronger biological rationale for FABP4’s role and advocates using Mendelian randomization to confirm its causal links. Incorporating machine learning and deep learning can yield more precise prognostic models. We also propose exploring multi-target strategies related to FABP4 and encourage future studies to combine experimental validation to reduce bioinformatics false positives. This allows us to elucidate underlying molecular biological mechanisms, offering fresh insights for personalized colon adenocarcinoma treatment.